Pre-made Intetumumab benchmark antibody ( Whole mAb, anti-ITGAV_ITGB3 therapeutic antibody, Anti-CD51/MSK8/VNRA/VTNR;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Intetumumab benchmark antibody (Whole mAb, anti-ITGAV_ITGB3 therapeutic antibody, Anti-CD51/MSK8/VNRA/VTNR;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Intetumumab is a human monoclonal antibody targeting integrins that was being studied for the treatment of solid tumors.
| Products Name (INN Index) | Pre-Made Intetumumab biosimilar, Whole mAb, Anti-ITGAV;ITGB3 Antibody: Anti-CD51/MSK8/VNRA/VTNR;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 therapeutic antibody |
|---|---|
| INN Name | Intetumumab |
| Target | ITGAV_ITGB3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2009 |
| Year Recommended | 2010 |
| Companies | Centocor Inc,Janssen Biotech,Janssen-Cilag |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Malignant melanoma,Prostate cancer |
| Development Tech | VelocImmune Mouse |
| Previous Name | NA |
| Gm Offical Target Name | ITGAV_ITGB3 |
| Package |
